Jupiter Neurosciences Launches Consumer Longevity Line Nugevia Using Patented JOTROL Technology

Jupiter Neurosciences Inc. has launched Nugevia, a direct-to-consumer product line utilizing its patented JOTROL technology, marking a strategic expansion into the longevity market while addressing the challenge of achieving therapeutic resveratrol levels without gastrointestinal side effects. The company's leadership emphasizes that JOTROL delivers 8-10 times higher blood plasma concentrations than conventional resveratrol with one-tenth the dose, enabling effective antioxidant, anti-inflammatory, and DNA repair benefits previously unattainable through standard supplements.

The development of Nugevia responds to growing consumer interest in evidence-based longevity solutions, with Jupiter Neurosciences distinguishing its offerings through clinical validation lacking in many competitors. Christer Rosen, Chairman and CEO, noted the dual advantage of creating cash flow through nutraceuticals while advancing pharmaceutical applications for central nervous system disorders like Alzheimer's and Parkinson's disease. The initial Nugevia formulations target specific health domains: Nugevia GLO focuses on skin radiance and hydration, Nugevia PWR enhances mitochondrial energy and recovery, and Nugevia MND supports cognitive function and brain health.

Rosen anticipates revenue generation beginning this year, accelerating with brand ambassador partnerships such as professional golfer Annika Sörenstam and expanded marketing outreach. He also addressed short seller pressure on the company's stock, expressing confidence that clinical and commercial execution will drive valuation alignment. The company's approach combines scientific innovation with consumer accessibility, potentially setting new standards for efficacy in the dietary supplement industry while bridging pharmaceutical research and everyday health optimization.